News

Zydus Lifesciences has launched VaxiFlu-4, India’s first quadrivalent influenza vaccine tailored for the 2025 Southern Hemisphere flu season. This vaccine aligns with the World Health Organization’s (WHO) recommended composition, offering comprehensive protection against four influenza virus strains: A/Victoria/4897/2022 (H1N1)pdm09-like virus: A strain of the H1N1 subtype, known for causing respiratory illnesses. A/Croatia/10136RV/2023 (H3N2)-like virus: A

India’s Contract Research, Development, and Manufacturing Organization (CRDMO) sector is poised for significant growth, with projections indicating an expansion to $22–$25 billion by 2035. This anticipated growth underscores India’s burgeoning role in the global pharmaceutical landscape, driven by a confluence of strategic advantages and emerging opportunities. Current Market Landscape As of 2025, India’s CRDMO market

In a significant move poised to revolutionize the life sciences sector, EY-Parthenon and Microsoft have collaboratively introduced an Artificial Intelligence (AI) Maturity Framework for Future of AI in Pharma. This strategic initiative, unveiled at BioAsia 2025, aims to guide organizations in the pharmaceutical, medical technology, and academic research fields toward effective AI integration, fostering innovation

The 10th Nutraceutical Summit, organized by ASSOCHAM, recently convened industry leaders, policymakers, and experts to discuss the pivotal role of nutraceuticals in preventive healthcare. The summit underscored the significance of regulatory advancements, market expansion, and the integration of traditional systems like Ayurveda in promoting health and wellness. Regulatory Advancements in the Nutraceutical Sector A central

Biocon Biologics, a subsidiary of Biocon Ltd., has announced the U.S. launch of YESINTEK (ustekinumab-kfce), a biosimilar to Janssen’s Stelara® (ustekinumab). This significant milestone positions Biocon Biologics among the first to introduce a Stelara® biosimilar in the United States, expanding treatment options for patients with autoimmune conditions. YESINTEK: A New Therapeutic Option YESINTEK is designed

Amgen, a leading U.S.-based biopharmaceutical company, has inaugurated a state-of-the-art technology and innovation hub in Hyderabad, India, named Amgen India. This strategic expansion involves an initial investment of $200 million through 2025, with plans for further significant investments in the coming years. Facility Overview Located in Hyderabad’s HITEC City, the Amgen India facility spans approximately

In February 2025, Dr. Jennifer Garvey Berger, co-founder and CEO of Cultivating Leadership, visited India to lead transformative leadership sessions in New Delhi and Mumbai. These events, organized in collaboration with the Confederation of Indian Industry (CII), aimed to equip Indian business leaders with strategies to navigate the complexities of modern business environments. The sessions

The European Union’s In Vitro Diagnostic Regulation (IVDR) has significantly reshaped the landscape of precision medicine development within the EU. Implemented to enhance the safety and reliability of in vitro diagnostic (IVD) devices, the IVDR introduces stringent requirements that have profound implications for stakeholders in the precision medicine sector. Lets discuss The Impact of IVDR